New headband zaps migraine pain in clinical trial
NCT ID NCT07015125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new wearable device that uses gentle electrical stimulation on the head and neck to relieve migraine pain. 160 people with migraines used the device during attacks, and researchers compared real stimulation to a sham (inactive) treatment. The goal was to see if the device provides safe and effective pain relief within one to two hours.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
160 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of migraine with or without aura, identified via participant-provided medical records. * Average migraine pain is 4 or more on the 0-10 Numerical Rating Scale (NRS) for pain. * Passes ID-Migraine pre-screening questions and has ID-Migraine score ≥ 2: a. ID-Migraine pre-screening questions: i. How many headaches have participants experienced within the previous 3 months? * Needs to be ≥ 6 headaches ii. Do the headaches that participants experience limit the ability to work, study, or enjoy life, or does the participant wish to speak with a healthcare professional about the headaches? (yes / no) * Participant needs to respond "yes" b. ID-Migraine questions: i. Over the last 3 months, did participants have any of the following with headaches? * Felt nauseated or sick to stomach (yes \[1\] / no \[0\]) * Light bothered them (a lot more than when headaches are not present)? (yes \[1\] / no \[0\]) * Headaches limited the ability to work, study, or do what needed to be done? (yes \[1\] / no \[0\]) * Able to understand and provide informed consent. * Age 18 and older. * US resident. * Has experienced migraines for at least 1 year prior to recruitment. * Onset of migraines occurred at age 50 years or younger. * Average of at least 2 migraines per month of moderate to severe intensity. * Is either on a) no medications or b) a stable dose of migraine-preventative medication for at least 2 months prior to recruitment. * Willing to refrain from altering preventive medication for migraines (or from using botox), commit to using Enso as the first-line treatment, and wait at least 2 hours after Enso treatment before using any additional abortives during the study period. * Participants must own an iPhone with iOS 15 or newer, or an Android phone with Android 9 or newer, with Bluetooth capability and access to either the Apple App Store (for iOS devices) or Google Play Store (for Android devices). * Has an email account. Exclusion Criteria: * Typical migraine pain is \< 4 out of 10 on the 0-10 NRS. * Currently institutionalized. * Currently is or has ever been a Hinge Health member. * Use of antipsychotic medication up to 3 months before study recruitment. * Diagnosis of cancer/malignant tumors in the last 5 years. * Cognitive, behavioral, neurologic, or psychiatric disorder (e.g., dementia, Parkinson's, schizophrenia, stroke) that may interfere with the study or prevent the subject from complying with the requirements of the protocol. * Has epilepsy. * Has a history of major cardiovascular events such as strokes, arrhythmias, or myocardial infarction. * Has a history of major migraine complications such as migrainous infarction or migraine aura-triggered seizure * Diagnosed with secondary headache disorders including medication overuse headaches * History of opioid, alcohol, or drug abuse in the last 1 year. * Has a cardiac pacemaker, implanted defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other implanted electronic device. * Has a metal implant in the upper extremities or head. * Has a history of major head or neck surgeries. * Pregnant. * Currently participating or has participated in a study with an investigational compound or device within the last 30 days before the screening visit. * Currently using a TENS device to treat migraines. * Received supraorbital nerve blocks or Botox treatment within 4 months prior to recruitment. * Insufficient proficiency with the English language to take part in study procedures or complete online surveys. * Planning to travel outside of the US within three months after consenting to the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Migraine are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hinge Health, Inc.
San Francisco, California, 94105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your toothpaste be triggering migraines? trial puts it to the test
- Can sleep, neck pain, and fatigue explain Migraine's daily toll?
- Do Gender-Affirming hormones trigger headaches? thai survey probes the question
- Can a pill stop a migraine in two hours?
- Can tai chi or acupuncture rewire the migraine brain?
- Could a migraine injection also heal caregiver burnout?